Prosecution Insights
Last updated: November 20, 2026
Application No. 17/934,799

HIGH PURITY gRNA SYNTHESIS PROCESS

Non-Final OA §103§DOUBLEPATENT
Filed
Sep 23, 2022
Priority
Sep 24, 2021 — provisional 63/248,102 +1 more
Examiner
ZARA, JANE J
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
CRISPR Therapeutics AG
OA Round
3 (Non-Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
788 granted / 1109 resolved
+11.1% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
49 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
5.4%
-34.6% vs TC avg
§103
30.6%
-9.4% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
33.1%
-6.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1109 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office action is in response to the communications filed 7-24-26. Claims 1-6, 23-31, 40, 61, 85, 86, 129 and 150 are pending in the instant application. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7-24-26 has been entered. Response to Arguments and Amendments Withdrawn Rejections Any rejections not repeated in this Office action are hereby withdrawn. New Rejections Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-6, 23-31, 40, 61, 85, 86, 129 and 150 is/are rejected under 35 U.S.C. 103 as being obvious over Cafferty et al (WO 2021/108647) in view of Daugharthy et al (US 2021/0381049). The claims are drawn to methods of synthesizing a guide RNA (gRNA) comprising providing a first RNA fragment comprising a terminal region comprising a first terminal region comprising a 5' phosphate moiety and a second terminal region comprising a 3' hydroxyl moiety, and a second RNA fragment comprising a terminal region comprising a 5' phosphate moiety, wherein the first RNA fragment, the second RNA fragment, or both comprise a sequence capable of binding to an RNA-guided endonuclease, providing a first splint DNA oligonucleotide comprising a first portion complementary to the first RNA fragment at the second terminal region comprising the 3' hydroxyl moiety and a second portion complementary to the second RNA fragment at the terminal region comprising the 5' phosphate moiety; hybridizing the first RNA fragment, the second RNA fragment, and the first splint DNA oligonucleotide together to form a first complex; contacting the first and second RNA fragments with a ligase to form a gRNA at a ligation site present between the first and second RNA fragments in the first complex to form a first portion of a gRNA; digesting the first splint DNA oligonucleotide with DNAse, providing a third RNA fragment comprising a terminal region comprising a 3' hydroxyl moiety and a second splint DNA oligonucleotide comprising a first portion complementary to the third RNA fragment at the terminal region comprising the 3' hydroxyl moiety and a second portion complementary to the first RNA fragment at the first terminal region comprising the 5' phosphate moiety; hybridizing the first portion of the gRNA, the third RNA fragment, and the second splint DNA oligonucleotide together to form a second complex; contacting the first and third RNA fragments with the ligase at a ligation site present between the first and third RNA fragments in the second complex to form the gRNA; and digesting the second splint DNA oligonucleotide with DNAse to obtain the gRNA. Cafferty et al (WO 2021/108647) teach methods of synthesizing a guide RNA (gRNA) comprising providing a first RNA fragment comprising a terminal region comprising a first terminal region comprising a 5' phosphate moiety and a second terminal region comprising a 3' hydroxyl moiety, and a second RNA fragment comprising a terminal region comprising a 5' phosphate moiety, wherein the first RNA fragment, the second RNA fragment, or both comprise a sequence capable of binding to an RNA-guided endonuclease, providing a first splint DNA oligonucleotide comprising a first portion complementary to the first RNA fragment at the second terminal region comprising the 5' phosphate 3' hydroxyl moiety and a second portion complementary to the second RNA fragment at the terminal region comprising the 5' phosphate moiety; hybridizing the first RNA fragment, the second RNA fragment, and the first splint DNA oligonucleotide together to form a first complex; contacting the first and second RNA fragments with a ligase to form a gRNA at a ligation site present between the first and second RNA fragments in the first complex to form a second complex a first portion of a gRNA; purifying the gRNA, providing a third RNA fragment comprising a terminal region comprising a 3' hydroxyl moiety and a second splint DNA oligonucleotide comprising a first portion complementary to the third RNA fragment at the terminal region comprising the 3' hydroxyl moiety and a second portion complementary to the first RNA fragment at the first terminal region comprising the 5' phosphate moiety; hybridizing the first portion of the gRNA, the third RNA fragment, and the second splint DNA oligonucleotide together to form a second complex; contacting the first and third RNA fragments with the ligase at a ligation site present between the first and third RNA fragments in the second complex to form the gRNA; and removing the second splint DNA oligonucleotide to obtain the gRNA (see entire document, esp. Fig. 1, Summary on pages 2, 3, 5, 6, 9, 15, 16, 25, 26, claims 1-108). Cafferty et al (WO 2021/108647) does not teach the treatment of the splint oligonucleotides with DNAse. Daugharthy et al (US 2021/0381049) teach the treatment of RNA with DNAse to remove DNA and purify the RNA molecules (see esp. para 0025, 0026). It would have been obvious to synthesize RNA using the fragments and splints instantly claimed because the prior art had taught all of the synthetic steps and components for making medium sized RNA, as illustrated in the teachings of Application No. 17/776, 822. One of skill in the art would have been motivated to incorporate the modifications instantly claimed to enhance target binding and stability of RNA fragments. One of skill in the art would have also been motivated to remove the DNA splints after ligation of the RNA fragments in order to obtain purified, synthesized RNA. Obvious ways to remove the splints and taught in the prior art include using gel isolation, attaching the RNA to a solid surface, or degrading the DNA splints using DNAse, which DNAse treatment of RNA was routinely disclosed in the prior art, as illustrated in the teachings of Daugharthy. For these and the aforementioned reasons, the instant invention would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. The applied reference has a common inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 103 might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C.102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B); or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-6, 23-31, 40, 61, 85, 86, 129 and 150 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, 6, 13, 16, 24, 25, 29-31, 40, 43, 50, 76, 77, 95 of copending Application No. 17/776, 822 (reference application) in view of Daugharthy et al (US 2021/0381049). Although the claims at issue are not identical, they are not patentably distinct from each other because both sets of claims are drawn to methods of synthesizing a guide RNA (gRNA) comprising providing a first RNA fragment comprising a terminal region comprising a first terminal region comprising a 5' phosphate moiety and a second terminal region comprising a 3' hydroxyl moiety, and a second RNA fragment comprising a terminal region comprising a 5' phosphate moiety, wherein the first RNA fragment, the second RNA fragment, or both comprise a sequence capable of binding to an RNA-guided endonuclease, providing a first splint DNA oligonucleotide comprising a first portion complementary to the first RNA fragment at the second terminal region comprising the 5' phosphate 3' hydroxyl moiety and a second portion complementary to the second RNA fragment at the terminal region comprising the 5' phosphate moiety; hybridizing the first RNA fragment, the second RNA fragment, and the first splint DNA oligonucleotide together to form a first complex; contacting the first and second RNA fragments with a ligase to form a gRNA at a ligation site present between the first and second RNA fragments in the first complex to form a second complex a first portion of a gRNA; purifying the gRNA, providing a third RNA fragment comprising a terminal region comprising a 3' hydroxyl moiety and a second splint DNA oligonucleotide comprising a first portion complementary to the third RNA fragment at the terminal region comprising the 3' hydroxyl moiety and a second portion complementary to the first RNA fragment at the first terminal region comprising the 5' phosphate moiety; hybridizing the first portion of the gRNA, the third RNA fragment, and the second splint DNA oligonucleotide together to form a second complex; contacting the first and third RNA fragments with the ligase at a ligation site present between the first and third RNA fragments in the second complex to form the gRNA; and removing the second splint DNA oligonucleotide to obtain the gRNA. Application No. 17/776, 822 does not teach purification of the gRNA using DNAse. Daugharthy et al (US 2021/0381049) teach the treatment of RNA with DNAse to remove DNA and purify the RNA molecules (see esp .para 0025, 0026). It would have been obvious to synthesize RNA using the fragments and splints instantly claimed because the prior art had taught all of the synthetic steps and components for making medium sized RNA, as illustrated in the teachings of Application No. 17/776, 822. One of skill in the art would have been motivated to incorporate the modifications instantly claimed to enhance target binding and stability of RNA fragments. One of skill in the art would have also been motivated to remove the DNA splints after ligation of the RNA fragments in order to obtain purified, synthesized RNA. Obvious ways to remove the splints and taught in the prior art include using gel isolation, attaching the RNA to a solid surface, or degrading the DNA splints using DNAse, which DNAse treatment of RNA was routinely disclosed in the prior art, as illustrated in the teachings of Daugharthy. For these and the aforementioned reasons, the instant invention would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Certain papers related to this application may be submitted to Art Unit 1637 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. The examiner’s office hours are generally Monday-Friday, 10:30am - 7pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jennifer Dunston, can be reached on (571)-272-2916. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Jane Zara 10-22-26 /JANE J ZARA/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Sep 23, 2022
Application Filed
Apr 03, 2023
Response after Non-Final Action
Jun 04, 2025
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Nov 12, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §103, §DOUBLEPATENT
Jul 24, 2026
Request for Continued Examination
Jul 28, 2026
Response after Non-Final Action
Oct 27, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799147
RIBONUCLEIC ACID PURIFICATION
3y 6m to grant Granted Nov 17, 2026
Patent 12774468
DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES
3y 1m to grant Granted Oct 27, 2026
Patent 12735704
ANTICANCER ADJUVANT AND PHARMACEUTICAL COMPOSITION FOR TREATING ANTICANCER-AGENT-RESISTANT CANCER, AND KIT COMPRISING SAME
3y 11m to grant Granted Sep 15, 2026
Patent 12734251
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
3y 7m to grant Granted Sep 15, 2026
Patent 12703734
METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS
2y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
87%
With Interview (+16.1%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1109 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month